ORIGINAL RESEARCH article
Front. Public Health
Sec. Aging and Public Health
Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1562701
This article is part of the Research TopicInsights in Rehabilitation for Musculoskeletal Conditions 2023/2024View all 6 articles
Global, regional, and national burden of musculoskeletal disorders, 1990–2021: An analysis of the global burden of disease study 2021 and forecast to 2035
Provisionally accepted- 1Hebei Provincial Children's Hospital, Shijiazhuang, China
- 2Second Hospital of Anhui Medical University, Hefei, Anhui Province, China
- 3Bai Qiu’en International Peace Hospital, Shijiazhuang, China
- 4Shenyang Pharmaceutical University, Shenyang, Liaoning Province, China
- 5The First Affiliated Hospital of the Chinese People’s Liberation Army Air Force University of Military Medicine, Shanxi, China
- 6North China Medical and Healthcare Group Huayao Hospital, Shijiazhuang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objectives: This study aimed to assess the global, regional, and national burdens of musculoskeletal disorders (MSDs) since 1990. It also projected trends up to 2035 and explored potential improvements through frontier analysis.Methods: Using data from the Global Burden of Disease 2021 study, MSDs in 204 countries and territories were analyzed. Age-standardized rates (ASRs) for prevalence (ASPR), incidence (ASIR), DALYs (ASDR), and mortality (ASMR) were calculated. Trends were evaluated through estimated annual percentage changes (EAPC). The Bayesian age-period-cohort (BAPC) model was employed for projections to 2035, and frontier analysis was used to assess the potential for reducing MSD burdens.In 2021, 1.686 billion MSDs prevalent cases were recorded globally, representing a 95% increase since 1990. Although total cases and DALYs have increased, ASIR and ASMR showed declining trends, with global MSD-related mortality decreasing by 0.265% annually.By 2035, the number of MSD cases is projected to rise to 2.161 billion, along with corresponding increases in DALYs and mortality, although ASRs are expected to continue declining. Frontier analysis revealed significant gaps between current burdens and achievable benchmarks, particularly in high-SDI regions, while some low-SDI regions demonstrated effective management despite limited resources. A U-shaped relationship between SDI and MSDs burdens was observed, with middle-SDI regions generally performing better.The global burden of MSDs is projected to rise in absolute case numbers, underscoring the necessity for strategically targeted interventions to manage their impact effectively. Frontier analysis illuminates potential improvements, particularly in high-SDI 3 countries, while projections indicate that enhanced access to healthcare and better resource distribution could alleviate the global MSDs burden. Addressing disparities and implementing tailored interventions are crucial for reducing MSDs-related disability and mortality.
Keywords: Musculoskeletal disorders, Epidemiology, Global burden of disease, Frontier analysis, Bayesian age-period-cohort model
Received: 22 Jan 2025; Accepted: 18 Jul 2025.
Copyright: © 2025 Liu, Rong, An, Li, Min, Yuan, Yang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Meizhi Liu, Hebei Provincial Children's Hospital, Shijiazhuang, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.